Cargando…
Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413692/ https://www.ncbi.nlm.nih.gov/pubmed/34493918 http://dx.doi.org/10.1007/s40274-021-07997-6 |
| _version_ | 1783747680274481152 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8413692 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84136922021-09-03 Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany PharmacoEcon Outcomes News Clinical Study Springer International Publishing 2021-09-04 2021 /pmc/articles/PMC8413692/ /pubmed/34493918 http://dx.doi.org/10.1007/s40274-021-07997-6 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Clinical Study Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title | Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title_full | Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title_fullStr | Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title_full_unstemmed | Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title_short | Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
| title_sort | remdesivir may be cost saving in eligible patients during covid-19 infections in germany |
| topic | Clinical Study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413692/ https://www.ncbi.nlm.nih.gov/pubmed/34493918 http://dx.doi.org/10.1007/s40274-021-07997-6 |